Attorney Docket No.: UM-02560



DECLARATION FOR PATENT APPLICATION

As a below-named inventor, I hereby declare that:


My residence, post office address and citizenship are as stated next to my name. I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled ADMINISTRATION OF PRODUCTS OF THE 5-LIPOXYGENASE METABOLIC PATHWAY TO ENHANCE ANTIMICROBIAL DEFENSE, the specification of which was filed on 12/03/96 as Application Serial No. 08/757,136. I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under § 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Fully Name of Sole or First Inventor: Marc Peters-Golden	
Inventor's Signature: Nace Peter Solde	Date: $\frac{17/97}{}$
Residence: 565 Green Road, Ann Arbor, Michigan 48105	Citizenship: United States of America
Post Office Address: 565 Green Road, Ann Arbor, Michigan 48105	
Full Name of Second Joint Inventor: Theodore Standiford Inventor's Signature:	Date: 2/17/97
Residence: 2981 Devonshire, Ann Arbor, Michigan 48104	Citizenship: United States of America
Post Office Address: 2981 Devonshire, Ann Arbor, Michigan 48104	





Applicant / Patentee:

Marc Peters-Golden et al. BEST AVAILABLE COPY

Serial No.: Filed:

08/757,136 12/03/96

For:

ADMINISTRATION OF PRODUCTS OF THE 5-LIPOXYGENASE

METABOLIC PATHWAY TO ENHANCE ANTIMICROBIAL DEFENSE

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS (37 CFR §§ 1.9(f) and 1.27(d) - NONPROFIT ORGANIZATION)

I hereby declare that I am an official empowered to act on behalf of the university (or other institution of higher education) identified below:

Regents of the University of Michigan 3003 South State Street, Ann Arbor, Michigan 48109-1280

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR § 1.9(e) for purposes of paying reduced fees under §§ 41(a) and (b) of Title 35, United States Code with regard to the invention entitled ADMINISTRATION OF PRODUCTS OF THE 5-LIPOXYGENASE

METABOLIC PATHWAY TO ENHANCE ANTIMICROBIAL DEFENSE, by inventors named Marc Peters-Golden et al., described in Application Serial No. 08/757,136, filed 12/03/96.

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR § 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

Date: Feb 8, 199

By:

Name:

Robert L. Robb

Title:

Director, Technology Management Office